First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors

被引：0
|
作者：
Tianhong Li
Patricia LoRusso
Michael L. Maitland
Sai-Hong Ignatius Ou
Erkut Bahceci
Howard A. Ball
Jung Wook Park
Geoffrey Yuen
Anthony Tolcher
机构：
[1] University of California Davis Comprehensive Cancer Center,Division of Hematology/Oncology
[2] Wayne State University,Karmanos Cancer Institute
[3] University of Chicago Medicine,Section of Hematology/Oncology, Committee on Clinical Pharmacology and Pharmacogenomics
[4] University of California Irvine School of Medicine,Chao Family Comprehensive Cancer Center
[5] Astellas Pharma Global Development,undefined
[6] South Texas Accelerated Research Therapies (START) Center for Cancer Care,undefined
[7] Present address: Yale Smilow Cancer Center,undefined
来源：
Journal of Hematology & Oncology | / 9卷
关键词：
ASP3026; Neoplasms; ALK inhibitor; Phase I; Pharmacokinetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] PROPEL2: a phase 2, open-label, dose-escalation and dose-expansion study of infigratinib in children with achondroplasia (ACH)
    Savarirayan, Ravi
    Arundel, Paul
    Maria De Bergua, Josep
    McDevitt, Helen
    Cormier-Daire, Valerie
    Saraff, Vrinda
    Skae, Mars
    Santos-Simarro, Fernando
    Salles, Jean Pierre
    Rossi, Massimiliano
    Kannu, Peter
    Bober, Michael B.
    Phillips, John, III
    Saal, Howard
    Harmatz, Paul
    Meireles, Ana Beleza
    Cho, Terry
    Muslimova, Elena
    Weng, Richard
    Rogoff, Daniela
    Irving, Melita
    HORMONE RESEARCH IN PAEDIATRICS, 2021, 94 (SUPPL 1): : 134 - 135
  • [42] Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label,phase Ⅰ dose escalation and dose expansion trial
    Yan Song
    Jinwan Wang
    Xiubao Ren
    Jie Jin
    Li Mao
    Chris Liang
    Lieming Ding
    Lin Yang
    ChineseJournalofCancerResearch, 2021, 33 (01) : 103 - 116
  • [43] A first-in-human dose-escalation study of ME-143, a second generation NADH oxidase inhibitor, in patients with advanced solid tumors
    Shubham Pant
    Howard A. Burris
    Kathleen Moore
    Johanna C. Bendell
    Carla Kurkjian
    Suzanne F. Jones
    Ofir Moreno
    John G. Kuhn
    Scott McMeekin
    Jeffrey R. Infante
    Investigational New Drugs, 2014, 32 : 87 - 93
  • [44] PROPEL2: a phase 2, open-label, dose-escalation and dose-expansion study of infigratinib in children with achondroplasia (ACH)
    Savarirayan, Ravi
    Arundel, Paul
    Maria De Bergua, Josep
    McDevitt, Helen
    Cormier-Daire, Valerie
    Saraff, Vrinda
    Skae, Mars
    Santos Simarro, Fernando
    Salles, Jean Pierre
    Rossi, Massimiliano
    Kannu, Peter
    Bober, Michael B.
    Phillips, John A., III
    Saal, Howard
    Harmatz, Paul
    Meireles, Ana Beleza
    Cho, Terry
    Muslimova, Elena
    Weng, Richard
    Rogoff, Daniela
    Irving, Melita
    JOURNAL OF BONE AND MINERAL RESEARCH, 2022, 37 : 93 - 93
  • [45] A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
    Michael S. Gordon
    David S. Mendelson
    Mitchell Gross
    Martina Uttenreuther-Fischer
    Mahmoud Ould-Kaci
    Yihua Zhao
    Peter Stopfer
    David B. Agus
    Investigational New Drugs, 2013, 31 : 409 - 416
  • [46] A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
    Gordon, Michael S.
    Mendelson, David S.
    Gross, Mitchell
    Uttenreuther-Fischer, Martina
    Ould-Kaci, Mahmoud
    Zhao, Yihua
    Stopfer, Peter
    Agus, David B.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (02) : 409 - 416
  • [47] AN OPEN-LABEL DOSE-ESCALATION TRIAL OF ORAL DEHYDROEPIANDROSTERONE TOLERANCE AND PHARMACOKINETICS IN PATIENTS WITH HIV DISEASE
    DYNER, TS
    LANG, W
    GEAGA, J
    GOLUB, A
    STITES, D
    WINGER, E
    GALMARINI, M
    MASTERSON, J
    JACOBSON, MA
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1993, 6 (05): : 459 - 465
  • [48] A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors
    Ghamande, Sharad
    Lin, Chia-Chi
    Cho, Daniel C.
    Shapiro, Geoffrey I.
    Kwak, Eunice L.
    Silverman, Michael H.
    Tseng, Yunlong
    Kuo, Min-Wen
    Mach, Wendy B.
    Hsu, Shu-Chi
    Coleman, Teresa
    Yang, James Chih-Hsin
    Cheng, Ann-Lii
    Ghalib, Mohammad H.
    Chuadhary, Imran
    Goel, Sanjay
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (03) : 445 - 451
  • [49] A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors
    Sharad Ghamande
    Chia-Chi Lin
    Daniel C. Cho
    Geoffrey I. Shapiro
    Eunice L. Kwak
    Michael H. Silverman
    Yunlong Tseng
    Min-Wen Kuo
    Wendy B. Mach
    Shu-Chi Hsu
    Teresa Coleman
    James Chih-Hsin Yang
    Ann-Lii Cheng
    Mohammad H. Ghalib
    Imran Chuadhary
    Sanjay Goel
    Investigational New Drugs, 2014, 32 : 445 - 451
  • [50] A phase I, 2-part, multicenter, first-in-human dose-escalation and dose-expansion study of DS-1103a with trastuzumab deruxtecan (T-DXd) in patients with advanced solid tumors
    Cavalcante, L.
    Siu, L. L.
    Toso, J.
    Mires, D.
    Shiga, R.
    Maruca, J.
    Ayele, G.
    Vuppala, P. Kumar
    Cheng, Y.
    Huang, L.
    Connolly, J. E.
    Ishimoto, Y.
    Sue, M.
    Bedard, P. L.
    ANNALS OF ONCOLOGY, 2023, 34 : S333 - S333
12345